Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 7;16(5):780-792.
doi: 10.1093/ckj/sfac258. eCollection 2023 May.

Practical approaches to building up a cardiorenal clinic

Rafael de la Espriella  1 , Marta Cobo Marcos  2   3 , Claudio Ronco  4   5   6 , Debasish Banerjee  7   8 , Miguel González  9   10 , José Luis Górriz  9   10 , Borja Quiroga  11 , María José Soler  12 , Javier Díez  3   13   14   15 , Julio Núñez  1   3   10
Affiliations
Review

Practical approaches to building up a cardiorenal clinic

Rafael de la Espriella et al. Clin Kidney J. .

Abstract

The population with concomitant heart and kidney disease (often termed 'cardiorenal' disease) is expected to grow, significantly impacting public health and healthcare utilization. Moreover, the cardiorenal nexus encompasses a bidirectional relationship that worsens prognosis and may complicate pharmacological management in often elderly and frail patients. Therefore, a more cohesive multidisciplinary team approach aiming to provide holistic, coordinated and specialized care would be a positive shift towards improving patient outcomes and optimizing healthcare resources. This article aims to define the organizational aspects and key elements for setting up a multidisciplinary cardiorenal clinical program as a potential healthcare model adapted to the particular characteristics of patients with cardiorenal disease.

Keywords: cardiorenal clinics; cardiorenal disease; cardiorenal program; heart failure; kidney disease.

PubMed Disclaimer

Conflict of interest statement

C.R. reports payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Asahi, Baxter, Biomerieux, Jafron, Medica and GE and participation on data safety monitoring boards/advisory boards for Baxter, Jafron and Biomerieux. D.B. reports research grants from Kidney Research UK and AstraZeneca ESR, payment for lecture fees from AstraZeneca and Vifor Pharma and participation on an advisory board for Bayer. J.L.G. reports consulting fees from Bayer, AstraZeneca and Boehringer Ingelheim; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Bayer, AstraZeneca, Novo Nordisk and Boehringer Ingelheim and support for attending meetings and/or travel from Vifor Pharma. B.Q. reports consulting fees, participation on data safety monitoring boards or advisory boards, support for attending meetings and/or travel and payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Novartis, AstraZeneca, Sandoz, Laboratorios Bial, Esteve, Sanofi-Genzyme and Otsuka and is the secretary of the Spanish Society of Nephrology. J.D. reports consulting fees and payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from AstraZeneca, Bayer and Vifor Pharma and consulting fees from GlaxoSmithKline. M.J.S. reports grants or contracts from Instituto Carlos III, Marató TV3 and Boehringer Ingelheim; honoraria for lectures from Novo Nordisk, Jansen, Boehringer Ingelheim, Mundipharma, AstraZeneca, Ingelheim Lilly, Vifor Pharma, ICU Medical, Fresenius and Travere Therapeutics; support for attending meetings and/or travel from Travere and participation on advisory boards for Novo Nordisk, Jansen, Boehringer Ingelheim, Mundipharma, AstraZeneca, Ingelheim Lilly, Vifor Pharma, ICU Medical, Fresenius, Travere Therapeutics and GE Healthcare. M.J.S. and J.N. are members of the CKJ editorial board. All other authors declare no competing interests.

Figures

Graphical Abstract
Graphical Abstract
Figure 1:
Figure 1:
Referral sources and multidisciplinary evaluation and management of related comorbidities.
Figure 2:
Figure 2:
General follow-up approach.
See this image and copyright information in PMC

References

    1. Bhatnagar R, Fonarow GC, Heidenreich PA et al. Expenditure on heart failure in the United States: the Medical Expenditure Panel Survey 2009–2018. JACC Heart Failure 2022;10:571–80. - PMC - PubMed
    1. Savarese G, Becher PM, Lund LH et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res 2022;doi: 10.1093/cvr/cvac013. - PubMed
    1. Mohebi R, Chen C, Ibrahim NE et al. Cardiovascular disease projections in the United States based on the 2020 census estimates. J Am Coll Cardiol 2022;80:565–78. - PMC - PubMed
    1. McDonagh TA, Metra M, Adamo M et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022;24:4–131. - PubMed
    1. McCullough PA, Amin A, Pantalone KM et al. Cardiorenal nexus: a review with focus on combined chronic heart and kidney failure, and insights from recent clinical trials. J Am Heart Assoc 2022;11:e024139. - PMC - PubMed